Chapter 4: The Closed System of Controlled Substance Distribution

The Closed System of Controlled Substance Distribution

Federal Controlled Substances Act (CSA)

• Purpose: Creates a closed system for controlled substance distribution via mandatory registration.

• Goal: Establishes national uniformity in controlled substance regulation.

• Enforcement: Primarily enforced by the Drug Enforcement Administration (DEA).

State vs. Federal Authority

• Conflict Resolution: State laws governing controlled substances must be stricter than federal law to avoid conflict.

• Pharmacist's Responsibility: Pharmacists are obligated to follow the stricter of the state or federal laws.

• Interagency Relationship: The DEA generally maintains a close working relationship with state pharmacy boards.

• Interstate Commerce: Federal regulation of controlled substances operates under a presumption of interstate commerce, giving federal authorities broad reach.

Definition of Narcotic

• Narcotic: Refers to natural or synthetic opium or opiates, or their derivatives.

• Inclusion: This definition includes cocaine, despite it not being an opiate derivative.

Classification of Controlled Substances

• Scheduling System: Controlled substances are placed into one of five schedules (C-I to C-V).

• Criteria: Placement depends on their potential for abuse and the degree to which they may cause physical or psychological dependence.

C-I Drugs

• Medical Use: No accepted medical use in treatment (unlike drugs in other schedules).

• Abuse Potential: Possess a high potential for abuse.

• Safety Information: Lack accepted information regarding their safety for use.

• Examples: Includes hallucinogens, some opiates, methaqualone, and unapproved gamma-hydroxybutyric acid (GHB).

Medical and Recreational Use of Marijuana

• State Legality: Legal for medical purposes in many states, and for recreational use in a few states.

• Federal Status: Remains a C-I drug under federal law, regardless of state statutes.

• Constitutional Rights: Federal courts have consistently held that patients do not have a constitutional right to obtain marijuana.

• Supreme Court Rulings: The U.S. Supreme Court ruled that federal agents can seize medical marijuana due to the presumption of interstate commerce and that marijuana buying cooperatives violate the CSA.

• Physician Protection: A federal court has held that the government cannot take action against physicians who merely recommend medical marijuana to patients.

C-II Drugs

• Abuse Potential: High potential for abuse.

• Dependence Potential: Abuse may lead to severe physical or psychological dependence.

• Examples: Opium and many other opiates (e.g., products containing hydrocodone), cocaine, stimulants (e.g., amphetamine, methamphetamine), and depressants (e.g., amobarbital, glutethimide, secobarbital, pentobarbital).

C-III Drugs

• Abuse Potential: Lesser potential for abuse than C-II drugs.

• Dependence Potential: Abuse may lead to moderate or low physical dependence or high psychological dependence.

• Composition: Often include C-II drugs combined with noncontrolled ingredients, in smaller dosages, or in less abusable dosage forms.

• Examples: Certain stimulants, anabolic steroids, dronabinol, ketamine, paregoric, and FDA-approved GHB.

• Strength Limits: Specific strength limits apply, such as $1.8 ext{ g}$ of codeine per $100 ext{ ml}$. Also limits for dihydrocodeinone, opium, morphine, and other drugs.

C-IV Drugs

• Abuse Potential: Lower potential for abuse than C-III drugs.

• Dependence Potential: Abuse may lead to limited physical or psychological dependence.

• Examples: Narcotic drugs like dextropropoxyphene; depressants such as alprazolam, chloral hydrate, barbital, benzodiazepines; stimulants like diethylpropion, phentermine; and tramadol.

C-V Drugs

• Abuse Potential: Low potential for abuse relative to C-IV drugs.

• Dependence Potential: Abuse may lead to limited physical or psychological dependence relative to C-IV drugs.

• Examples: Antitussives containing codeine and antidiarrheals containing an opiate.

• Strength Limits: Specific strength limits, including $200 ext{ mg}$ of codeine per $100 ext{ ml}$, $100 ext{ mg}$ of dihydrocodeine or opium per $100 ext{ ml}$, $1.5 ext{ mg}$ of diphenoxylate, and no more than $25 ext{ mcg}$ atropine per dosage unit.

Authority for Scheduling

• Primary Authority: Vested in the Attorney General (AG).

• Consultation Requirement: The AG must request a scientific and medical evaluation and recommendation from the Secretary of the Department of Health and Human Services (DHHS).

• Binding Recommendation: The Secretary's recommendation on scientific and medical matters is binding on the AG.

• Exception: The AG can act independently to place a drug in C-I if there is an imminent hazard to public safety.

• Decision Factors: Scheduling decisions must be based on several factors, including actual or relative potential for abuse, scientific evidence of pharmacological effect, current knowledge of the drug, history and current pattern of abuse, scope/duration/significance of abuse, public health risk, psychic or physiological dependence liability, and whether the substance is an immediate precursor of a substance already controlled.

Manufacturer Labeling and Packaging

• Labeling Requirement: Commercial containers of controlled substances must prominently display the identification symbol of their respective schedule (e.g., C-II, C-III).

Registration

• Mandatory Registration: Anyone involved in manufacturing, distributing, or dispensing controlled substances must register with the DEA.

• Registration Frequency:

  • Manufacturers and distributors must register annually.

  • Dispensers must register every $3$ years.

• Exemptions from Registration:

  • Agents or employees of registrants.

  • Common carriers.

  • Ultimate users (patients).

  • Prescribers and dispensers acting in the service of the U.S. government within the scope of their official duties.

  • Law enforcement officers within the scope of their official duties.

Individual Practitioners (IPs)

• Definition: IPs include physicians, dentists, veterinarians, or other individuals licensed by the state to dispense.

• Agents/Employees: IPs who are agents or employees of another IP (excluding mid-level practitioners) may administer or dispense controlled substances, but they may not prescribe them under the employer's DEA registration.

• Hospital/Institutional IPs: IPs who are agents or employees of a hospital or other institution may administer, dispense, and prescribe controlled substances if all requirements are met, including the institution assigning a specific internal code number to the IP as a suffix to the institution's DEA number.

Activities Requiring Registration

• Manufacturing

• Distributing

• Reverse distributing

• Dispensing

• Conducting research

• Conducting narcotic treatment programs

• Conducting chemical analysis

• Importing

• Exporting

Dispensing

• Definition of Dispense: To deliver a controlled substance (CS) pursuant to a lawful order of a practitioner. This definition includes prescribing, administering, and the act of dispensing itself.

• Definition of Practitioner: Includes physicians, dentists, veterinarians, scientific investigators, pharmacies, pharmacists, hospitals, or others licensed by their jurisdiction to be involved with controlled substances.

• Institutional Practitioner: Specifically includes hospitals, but not pharmacies.

• Mid-level Practitioners: Including pharmacists, may register as dispensers, provided that state law authorizes them with independent or collaborative prescriptive authority.

Manufacturing

• Definition: Encompasses the production, preparation, compounding, or processing of a drug. It also includes packaging, repackaging, labeling, or relabeling.

• Exclusions: Excludes activities of practitioners that are incidental to their dispensing practice.

• Manufacturer Coincidental Activities: May include distributing their own products, conducting chemical analysis, and preclinical research.

• Pharmacy Exemption: Pharmacies are generally exempt from manufacturer registration if their activities are within the ordinary course of pharmacy practice.

  • Limits for Pharmacies: A pharmacy may manufacture and distribute to other practitioners an aqueous or oleaginous solution or solid dosage form of a narcotic, provided the narcotic concentration does not exceed 20 ext{%}.

Distributing

• Definition: To deliver a controlled substance.

• Wholesalers: Must register as distributors.

• Practitioner Exemption: Practitioners registered to dispense are exempt from distributor registration, provided they comply with all conditions regarding limited distribution (the "5 ext{%} rule").

• Other Exemptions:

  • Stocking of automated dispensing systems (ADS) in Long-Term Care Facilities (LTCF).

  • Return of controlled substances to suppliers by practitioners.

• Condition for Exemptions: Recordkeeping requirements must be met for these exemptions.

• Suspicious Orders: Distributors (and now all registrants) are required to design and operate a system capable of detecting suspicious orders of controlled substances and must inform the DEA upon discovery.

• Controversy: There is ongoing debate whether the delivery of controlled substances to a patient's prescriber constitutes distributing or dispensing.

Conducting Research

• Coincidental Activity: Dispensers may conduct research with Schedule II–V controlled substances if authorized.

• C-I Drug Research: Requires the submission of specific protocols along with the application for registration.

Separate Registrations Required

• Each principal place of business where controlled substances are administered, dispensed, or stored requires a separate DEA registration.

Application for Registration and Reregistration

• Activity Prohibition: No individual or entity may engage in an activity requiring registration until the registration is granted and a certificate of registration is issued.

• Reregistration Reminders: Current registrants typically receive emails reminding them of registration expiration.

• Dispenser Form: The dispenser registration form is DEA Form $224$, which is available and renewed online.

Modification, Transfer, or Termination of Registration

• Modifications: Any changes to registration information must be approved by the DEA.

• Death or Cessation of Legal Existence: If a registrant dies or ceases legal existence, the DEA must be notified, and the registration terminated.

• Assignment/Termination: Registrations cannot be assigned to another entity or terminated without explicit DEA approval.

Distribution of Controlled Substances on Discontinuance of Business

• Without Transfer: If a business discontinues operations without transferring the business, the registrant must return the certificate of registration to the DEA for cancellation, along with any unexecuted DEA Form $222$s (for C-I and C-II substances).

• Disposal: All controlled substances must be disposed of in accordance with DEA regulations.

• With Transfer: If the registrant intends to transfer the business, a proposal must be submitted to the DEA at least $14$ days prior to the proposed transfer date, including all required information.

  • DEA Notification: The transfer may proceed unless the DEA notifies the registrant otherwise.

  • Inventory: A complete inventory of all controlled substances must be taken on the date of transfer.

  • C-II Products: Schedule C-II products transferred must be recorded via DEA Form $222$.

Denial, Revocation, or Suspension of Registration

• Denial of Practitioner Application: The Attorney General (AG) may deny a practitioner applicant a registration if it is determined not to be in the public interest. This determination requires consideration of five specific factors related to public safety and drug control.

• Suspension or Revocation: The AG may suspend or revoke a registration (for manufacturing, distributing, or dispensing) if the applicant:

  • Materially falsified an application.

  • Has been convicted of a felony related to controlled substances.

  • Has had a state license or registration suspended, revoked, or denied concerning controlled substances.

Security Requirements

• General Mandate: All applicants and registrants must implement effective controls and procedures to guard against theft and diversion of controlled substances.

• DEA Evaluation Factors: The DEA considers several factors when evaluating the overall security system of a registrant or applicant.

• Individual Practitioners (IPs): IPs must securely lock controlled substances in a substantially constructed cabinet.

• Pharmacies and Institutional Practitioners: May choose to either securely lock controlled substances in a cabinet or disperse them throughout the stock of noncontrolled substances to deter theft, or a combination of both.

• Employment Restriction: Registrants may not employ any person whose application for registration has been denied or revoked for reasons related to controlled substances.

Penalties

• Section $841$ (Drug Trafficking): Establishes penalties for drug traffickers. This section is applicable to practitioners who prescribe and/or dispense controlled substances outside of the ordinary course of professional practice (i.e., for illegitimate purposes).

• Section $842$ (Non-Conforming Practitioners): Establishes penalties for practitioners who fail to conform to the requirements of the CSA, such as recordkeeping regulations. The legal standard for violation was changed from strict liability to negligence.

• DEA Form $222$ Violations: Subject to significant fines of up to tens of thousands of dollars and imprisonment for up to $4$ years.

• Unlawful Possession: Knowingly or intentionally possessing a controlled substance without a valid prescription can result in imprisonment for up to $1$ year and a fine of up to $1,000$.

Pharmacy Inspections

• Constitutional Issues (Fourth Amendment): Protects individuals from unreasonable searches and seizures.

  • Generally requires a search warrant based on probable cause.

  • Exclusionary Rule: Evidence obtained in violation of the Fourth Amendment is inadmissible in court.

DEA Inspections

• Authority: The DEA has the authority to inspect any place where controlled substance records are kept or where registered persons operate.

• Scope of Inspection: Inspectors are allowed to:

  • Examine and copy all relevant records and reports.

  • Inspect within reasonable limits.

  • Take an inventory of controlled substances.

• Limitations Without Consent: Without the express consent of the owner or person in charge (PIC), inspectors are generally not allowed to inspect financial, sales (other than shipping), or pricing data.

• Audit Procedure: Involves inspecting records of drugs received, subtracting drugs dispersed, and comparing the result with the physical inventory.

• Pre-Inspection Requirements: Prior to an inspection, the inspector is required to:

  • State the purpose of the inspection.

  • Present credentials.

  • Present a written notice of inspection to the owner or PIC.

Notice of Inspection (NOI)

• Content: The NOI must include the name of the owner or PIC, the name and address of the business, the date and time of the inspection, and a statement confirming that the NOI was given.

• Informed Consent: The inspector must obtain a written statement of informed consent signed by the PIC or owner.

  • Conditions: Consent must be voluntary, not coerced, and may be withdrawn at any time during the inspection.

  • Limited Consent: The PIC or owner can grant the inspector limited consent, specifying the scope of the inspection they permit.

Administrative Inspection Warrant (AIW)

• Consent: No consent is required for an inspection conducted under an AIW.

• Probable Cause Requirement: Based on a "valid public interest," which is a less stringent standard than the probable cause required for a standard criminal search warrant (SW).

• Origin: The AIW was created by the U.S. Supreme Court as an alternative to the SW for administrative purposes.

• Service Hours: An AIW may only be served during regular business hours.

• Exceptions: Several exceptions exist where a warrant (either SW or AIW) is not required for an inspection (e.g., emergency situations, inspectable areas in plain view, consent given, or for closely regulated industries).

State Pharmacy Board Inspections

• Warrantless Searches: Some states permit warrantless searches of pharmacies.

• Constitutionality: State warrantless search statutes may be constitutional if they meet certain requirements for closely regulated industries, such as a substantial government interest, necessary for the regulatory scheme, and providing a constitutionally adequate substitute for a warrant (e.g., notice).

Practical Considerations During an Inspection

• Cooperation: Be cordial and cooperative with inspectors.

• Non-Routine Inspections: If an inspection appears to be non-routine (e.g., unusually aggressive, focusing on criminal activity), the PIC should contact the owner and, if necessary, an attorney.

• Warrants: If DEA agents have a warrant (SW or AIW), inspection cannot be refused.

• No Warrant (State Inspectors): Whether consent is required for state inspectors without a warrant depends on specific state law.

• Communication: Never lie. It is generally best to say as little as possible to avoid inadvertently making admissions that could be used against the registrant.

• Documentation: Document everything said and done during the inspection. Do not sign anything that is not fully understood or agreed upon.

Opioid Treatment Programs (OTPs)

• Authorization: Congress first authorized what were then called narcotic treatment programs (now OTPs) in $1974$.

• Authorized Drugs: Currently, only LAAM (levo-alpha-acetylmethadol), methadone, buprenorphine, and buprenorphine-containing products are federally authorized for the treatment of opioid addiction in OTPs.

• Practitioner Registration: Practitioners intending to conduct maintenance or detoxification treatment programs must register with the DEA specifically for this purpose.

Methadone

• Pain Management: Used for severe pain outside of narcotic treatment programs.

• Antitussive Use: It is not legal to prescribe or dispense methadone as an antitussive (cough suppressant).

• APhA Lawsuit: The American Pharmacists Association (APhA) successfully sued to prevent the FDA from restricting the distribution of methadone for pain treatment.

• Voluntary Restriction: Manufacturers voluntarily restricted the distribution of $40 ext{ mg}$ methadone tablets exclusively to OTPs, aiming to reduce diversion for addiction treatment outside of structured programs.

Drug Addiction Treatment Act (DATA) of $2000$

• Intent: Enacted to allow individuals struggling with opioid addiction to receive treatment in office-based settings, outside of traditional OTPs.

• Permitted Drugs: Currently, only buprenorphine products are permitted for treatment under DATA.

• Qualifying Practitioner: Treatment must be provided by a "qualifying practitioner."

  • Requirements: Historically, this required a DEA registration with an 'X' waiver and state authorization to prescribe buprenorphine for OUD.

  • $2023$ Changes: As of $2023$, the requirement for a separate DEA 'X' number (waiver) has been eliminated. There are also no longer patient limits for qualifying practitioners.

• Goal: To significantly increase the number of practitioners able to treat Opioid Use Disorder (OUD) patients, potentially including pharmacists if states grant them the necessary prescriptive authority.

Controlled Substance Registrant Protection Act

• Purpose: Makes it a federal crime to rob a DEA registrant of controlled substances under specific circumstances.

• Conditions for Federal Crime: A federal crime if the robbery results in:

  • $500$ or greater replacement cost of controlled substances.

  • A person suffers a "significant" injury.

  • Interstate commerce is involved in the planning or execution of the crime.

• Penalties: Can lead to imprisonment for up to $20$ years, a $25,000$ fine, or both. Penalties are higher if a dangerous weapon is used, and even higher if death results.

Anabolic Steroids Act of $2004$

• Amendment: Amends prior anabolic steroid legislation, specifically targeting misuse to enhance athletic performance.

• Scheduling: Maintains anabolic steroids as Schedule III controlled substances.

• Additions: Adds several new steroids to the list of controlled substances.

• Automatic Scheduling: Provides for the automatic scheduling of certain salts, esters, and ethers of anabolic steroids, removing the need to prove their muscle-growth capabilities individually.

Combat Methamphetamine Epidemic Act of $2005$ and Methamphetamine Prevention Act of $2008$

• Restrictions: Places significant restrictions on the over-the-counter (OTC) sale of drugs used to manufacture methamphetamine, primarily pseudoephedrine (PSE), ephedrine, and phenylpropanolamine (PPA).

• Sales Limits:

  • Daily Limit: No more than $3.6 ext{ g}$ of ephedrine, PSE, or PPA base to a single purchaser per day.

  • $30$-day Limit (In-person): No consumer may purchase more than $9 ext{ g}$ within a $30$-day period.

  • $30$-day Limit (Mail Order): No consumer may purchase more than $7.5 ext{ g}$ within a $30$-day period by mail order.

• Storage Requirements: Products must be stored behind the counter or in a locked cabinet, preventing direct customer access.

• Sales Records: Sales must be recorded with required information, including purchaser's signature, name, address, date, and time of sale.

• State Laws: Many states have enacted even stricter laws than these federal mandates.

Methamphetamine Production Prevention Act of $2008$

• Electronic Logbooks: While not strictly required, the act encouraged the adoption of electronic logbooks as a standard and promoted participation in common electronic logbook systems among pharmacies.

• Information Capture: Sellers are now permitted to capture purchaser information using barcode readers.

• Data Entry: Either the seller or the purchaser may enter the purchaser's name, address, and the date and time of sale.

• Signature Collection: The seller may collect the purchaser's signature by any of three specified means.

• Self-Certification: Sellers (retailers) must annually engage in self-certification with the DEA confirming their compliance with the regulations.

U.S. Postal Laws

• Mailing Controlled Substances: Controlled substances may be mailed, provided they meet the specific packaging standards established by the U.S. Postal Service to prevent detection and diversion.